Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.
In postmenopausal women, who have increased sympathetic outflow, to test the hypothesis that treatment with low doses of a non-selective β-blocker (propranolol) will increase serum markers of bone formation and reduce markers of bone resorption (Aim 1a); and using increasingly β1-AR (adrenergic receptor) selective blockers (atenolol and nebivolol), to better define the β-adrenergic receptor selectivity (β1 versus β2) in the regulation of bone turnover by sympathetic outflow in humans.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| placebo | Placebo Comparator | Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose |
|
| Atenolol | Active Comparator | Atenolol 50 mg 1/day for 20 weeks |
|
| Nebivolol | Active Comparator | Nebivolol 5 mg/day for 20 weeks |
|
| Propranolol 40 mg | Active Comparator | Propranolol 20 mg bid for 20 weeks |
|
| Propranolol 80 mg | Active Comparator | Propranolol 40 mg bid for 20 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atenolol | Drug | beta blocker |
| |
| Nebivolol |
| Measure | Description | Time Frame |
|---|---|---|
| Ratio of serum bone formation to bone resorption marker | Serum bone formation marker (PINP)/serum bone resorption marker (CTX) | 20 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
adrenocorticosteroids (> 3 months at any time or > 10 days within the previous yr)
anticonvulsant therapy (within the previous year)
pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal)
calcium supplementation of > 1200 mg/d (within the preceding 3 months)
bisphosphonates (within the past 3 yrs)
denosumab
estrogen (E) therapy within the past year
treatment with a selective E receptor modulator within the past year
teriparatide within the past yr
anti-hypertensive therapy
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sundeep Khosla, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30153111 | Derived | Khosla S, Drake MT, Volkman TL, Thicke BS, Achenbach SJ, Atkinson EJ, Joyner MJ, Rosen CJ, Monroe DG, Farr JN. Sympathetic beta1-adrenergic signaling contributes to regulation of human bone metabolism. J Clin Invest. 2018 Nov 1;128(11):4832-4842. doi: 10.1172/JCI122151. Epub 2018 Oct 2. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010024 | Osteoporosis |
| ID | Term |
|---|---|
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001262 | Atenolol |
| D000068577 | Nebivolol |
| D011433 | Propranolol |
| ID | Term |
|---|---|
| D050198 | Phenoxypropanolamines |
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
beta blocker |
|
| Propranolol | Drug | beta blocker |
|
| placebo | Drug | placebo |
|
| D009750 |
| Nutritional and Metabolic Diseases |
| D009930 |
| Organic Chemicals |
| D020005 | Propanols |
| D000588 | Amines |
| D004983 | Ethanolamines |
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D011083 | Polycyclic Compounds |